Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1350 | Ejaculated semen sample Wiki | 0.58 |
| drug2224 | M5049 Wiki | 0.41 |
| drug1306 | EIDD-2801 Wiki | 0.33 |
Navigate: Correlations HPO
There are 3 clinical trials
The primary objectives are: Phase 1 - To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo - To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral shedding of SARS-CoV-2 Phase 2 • To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral shedding of SARS-CoV-2 Phase 3 • To evaluate the clinical efficacy of REGN10933+REGN10987 compared to placebo
Description: Primary: Phase 1 Secondary: Phase 2, Phase 3
Measure: Proportion of patients with treatment-emergent serious adverse events (SAEs) Time: Through Day 29Description: Primary: Phase 1 Secondary: Phase 2, Phase 3
Measure: Proportion of patients with infusion-related reactions Time: Through Day 4Description: Primary: Phase 1 Secondary: Phase 2, Phase 3
Measure: Proportion of patients with hypersensitivity reactions Time: Through Day 29Description: Primary: Phase 1, Phase 2 Secondary: Phase 3
Measure: Time-weighted average change from baseline in viral shedding as measured by quantitative reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples Time: Baseline up to Day 22Description: Primary: Phase 3 Secondary: Phase 1, Phase 2
Measure: Proportion of patients with at least one COVID-19 related medically attended visit Time: Through Day 29Description: Phase 1 Only
Measure: Time-weighted average change from baseline in viral shedding measured by RT-qPCR in saliva samples Time: Baseline up to Day 22Description: Phase 1 Only
Measure: Time-weighted average change from baseline in viral shedding measured by RT-qPCR in nasal swab samples Time: Baseline up to Day 22Description: Phase 1 Only
Measure: Time to negative RT-qPCR in all tested samples with no subsequent positive RT-qPCR in any tested samples Time: Through Day 29Description: Phase 2, Phase 3
Measure: Time to negative RT-qPCR in NP swabs with no subsequent positive RT-qPCR Time: Through Day 29Description: Phase 1 Only
Measure: Change from baseline in viral shedding as measured by RT-qPCR in saliva samples Time: Baseline up to Day 29Description: Phase 1 Only
Measure: Change from baseline in viral shedding as measured by RT-qPCR in nasal swabs Time: Baseline up to Day 29Description: Phase 1 Only
Measure: Correlation of RT-qPCR results over time between different sample types (NP, nasal, and saliva) Time: Up to Day 29Description: Phase 1 Only
Measure: Concordance of RT-qPCR results over time between different sample types (NP, nasal, and saliva) Time: Up to Day 29Description: Phase 1 Phase 2
Measure: Proportion of patients with at least two COVID-19 related medically attended visits Time: Through Day 29Description: Phase 2, Phase 3
Measure: Proportion of patients admitted to an intensive care unit (ICU) due to COVID-19 Time: Through Day 29Description: Phase 2, Phase 3
Measure: Proportion of patients requiring mechanical ventilation due to COVID-19 Time: Through Day 29Description: Phase 2, Phase 3
Measure: Number of days of hospitalization due to COVID-19 Time: Through Day 29Description: Phase 2, Phase 3
Measure: Number of deaths due to any cause (All-Cause Mortality) Time: Through Day 29Description: Phase 2
Measure: Time to first onset of symptoms consistent with COVID-19 (asymptomatic cohort only) Time: Up to Day 29Description: Phase 2
Measure: Duration of symptoms consistent with COVID-19 Time: Up to Day 29Description: Phase 1 only
Measure: Assessment of pharmacokinetic (PK) parameter: maximum serum concentration observed (Cmax) of REGN10933 Time: Through Day 29Description: Phase 1 only
Measure: Assessment of PK parameter: maximum serum concentration observed (Cmax) of REGN10987 Time: Through Day 29Description: Phase 1 only
Measure: Assessment of PK parameter: Cmax-to-dose ratio (Cmax/dose) of REGN10933 Time: Through Day 29Description: Phase 1 only
Measure: Assessment of PK parameter: Cmax-to-dose ratio (Cmax/dose) of REGN10987 Time: Through Day 29Description: Phase 1 only
Measure: Assessment of PK parameter: Time to Cmax (tmax) for REGN10933 Time: Through Day 29Description: Phase 1 only
Measure: Assessment of PK parameter: Time to Cmax (tmax) for REGN10987 Time: Through Day 29Description: Phase 1 only
Measure: Assessment of PK parameter: Area Under the Curve (AUC) computed from time zero to the time of the last positive concentration (AUClast) for REGN10933 Time: Through Day 29Description: Phase 1 only
Measure: Assessment of PK parameter: AUC computed from time zero to the time of the last positive concentration (AUClast) for REGN10987 Time: Through Day 29The primary objectives are: Phase 1 - To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo - To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral shedding of SARS-CoV-2 Phase 2 - To evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral shedding of SARS-CoV-2 - To evaluate the clinical efficacy of REGN10933+REGN10987 compared to placebo in improving clinical status Phase 3 - To evaluate and confirm the clinical efficacy of REGN10933+REGN10987 compared to placebo in improving clinical status
Description: Primary: Up to Day 169: Phase 1: C1 Secondary: Up to Day 29: Phase 1: C1, Phase 2: C1A, C1, C2, C3 Up to Day 57: Phase 2: C1A, C1, C2, C3
Measure: Proportion of patients with treatment-emergent Serious Adverse Events (SAEs) Time: Through Day 169Description: Primary: Phase 1:C1 Secondary: Phase 2: C1A, C1, C2, C3
Measure: Proportion of patients with infusion-related reactions Time: Through Day 4Description: Primary: Phase 1:C1 Secondary: Phase 2: C1A, C1, C2, C3
Measure: Proportion of patients with hypersensitivity reactions Time: Through Day 29Description: Phase 1:C1 Phase 2: C1A, C1, C2, C3
Measure: Time-weighted average change from baseline in viral shedding as measured by quantitative reverse transcription polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples Time: Baseline up to Day 22Description: Primary: Day 8: Phase 2: C1A, C1, Phase 3:C1 Day 22: Phase 2:C2, C3, Phase 3:C2, C3 Secondary: Day 8: Phase 1:C1 Day 29: Phase 1:C1, Phase 2: C1A, C1, C2, C3 7-point Ordinal Scale: Death; Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; Hospitalized, requiring supplemental oxygen; Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care Not hospitalized
Measure: Proportion of patients with at least 1-point improvement on a 7-Point Ordinal Scale in clinical status Time: From Day 1 up to Day 29Description: Phase 1: C1
Measure: Time-weighted average change from baseline in viral shedding as measured by RT-qPCR in saliva samples Time: Baseline up to Day 22Description: Phase 1: C1
Measure: Time-weighted average change from baseline in viral shedding as measured by RT-qPCR in nasal samples Time: Baseline up to Day 22Description: Phase 1: C1
Measure: Time to negative RT-qPCR in all tested samples with no subsequent positive RT-qPCR in any tested samples Time: Through Day 29Description: Phase 2: C1A, C1, C2, C3
Measure: Time to negative RT-qPCR in NP swabs with no subsequent positive RT-qPCR Time: Through Day 29Description: Phase 1: C1 Phase 2: C1A, C1, C2, C3
Measure: Change from baseline in viral shedding as measured by RT-qPCR in NP swabs Time: Baseline up to Day 29Description: Phase 1: C1 Phase 2: C1A, C1, C2, C3
Measure: Time-weighted average change in viral shedding Time: Baseline up to Day 29Description: Phase 1: C1
Measure: Change from baseline in viral shedding as measured by RT-qPCR in saliva samples Time: Baseline up to Day 29Description: Phase 1: C1
Measure: Change from baseline in viral shedding as measured by RT-qPCR in nasal swabs Time: Baseline up to Day 29Description: Phase 1: C1
Measure: Correlation of RT-qPCR results over time between different sample types Time: Up to Day 29Description: Phase 1: C1
Measure: Concordance of RT-qPCR results over time between different sample types Time: Up to Day 29Description: Phase 1: C1, Phase 2: C1A, C1 Day 8 Phase 2: C2, C3 Day 22 Phase 1: C1, Phase 2: C1A, C1, C2, C3 Day 29
Measure: Proportion of patients with at least 2-point improvement on a 7-Point Ordinal Scale in clinical status Time: From Day 1 up to Day 29Description: Phase 1: C1 Phase 2: C1, C2, C3
Measure: Time to no longer requiring oxygen supplementation Time: Through Day 29Description: Phase 1: C1 Phase 2: C1A, C1, C2, C3
Measure: Number of days of supplemental oxygen use Time: Through Day 29Description: Phase 1: C1 Phase 2: C1A, C1, C2, C3
Measure: Proportion of patients initiating high-intensity oxygen therapy Time: Up to Day 29 or hospital dischargeDescription: Phase 1: C1 Phase 2: C1A, C1, C2, C3
Measure: Number of days of high-intensity oxygen therapy Time: Through Day 29Description: Phase 1: C1 Phase 2: C1A, C1, C2, C3
Measure: Proportion of patients initiating mechanical ventilation Time: Up to Day 29 or hospital dischargeDescription: Phase 1: C1 Phase 2: C1A, C1, C2, C3
Measure: Number of days of mechanical ventilation Time: Through Day 29Description: Phase 1: C1 Phase 2: C1A, C1, C2, C3
Measure: Number of Ventilator-free days Time: Through Day 29Description: Phase 1: C1 Phase 2: C1A, C1, C2, C3
Measure: Number of days of hospitalization Time: Through Day 29Description: Phase 1: C1: Through Day 169 Phase 2: C1A, C1, C2, C3: Through Day 57
Measure: Proportion of patients re-admitted to hospital after discharge through the end of study Time: Through Day 169Description: Phase 1: C1 Phase 2: C1A, C1, C2, C3
Measure: Proportion of patients admitted into an intensive care unit (ICU) Time: Up to Day 29Description: Phase 1: C1 Phase 2: C1A, C1, C2, C3
Measure: Days of ICU stay Time: Up to Day 29Description: Phase 1: C1 Through Day 29 and Day 169 Phase 2: C1A, C1, C2, C3 Through Day 29 and Day 57
Measure: Number of deaths due to any cause (All-Cause Mortality) Time: Through Day 169Description: Phase 1: C1: Through Day 169 Phase 2: C1A, C1, C2, C3: Through Day 57
Measure: Overall Survival Time: Through Day 169Description: Phase 1: C1: Through Day 169 Phase 2: C1A, C1, C2, C3: Through Day 29
Measure: Serum concentration of REGN10933 over time Time: Through Day 169Description: Phase 1: C1: Through Day 169 Phase 2: C1A, C1, C2, C3: Through Day 29
Measure: Serum concentration of REGN10987 over time Time: Through Day 169Description: Phase 1: C1: Through Day 169 Phase 2: C1A, C1, C2, C3: Through Day 29
Measure: Incidence of anti-drug antibodies (ADA) to REGN10933 Time: Through Day 169Description: Phase 1: C1: Through Day 169 Phase 2: C1A, C1, C2, C3: Through Day 29
Measure: Incidence of anti-drug antibodies (ADA) to REGN10987 Time: Through Day 169Description: Phase 1 only
Measure: Assessment of pharmacokinetic (PK) parameter: maximum serum concentration observed (Cmax) of REGN10933 Time: Through day 169Description: Phase 1 only
Measure: Assessment of PK parameter: maximum serum concentration observed (Cmax) of REGN10987 Time: Through day 169Description: Phase 1 only
Measure: Assessment of PK parameter: Cmax-to-dose ratio (Cmax/dose) for REGN10933 Time: Through Day 169Description: Phase 1 only
Measure: Assessment of PK parameter: Cmax-to-dose ratio (Cmax/dose) for REGN10987 Time: Through Day 169Description: Phase 1 only
Measure: Assessment of PK parameter: Time to Cmax (tmax) for REGN10933 Time: Through Day 169Description: Phase 1 only
Measure: Assessment of PK parameter: Time to Cmax (tmax) for REGN10987 Time: Through Day 169Description: Phase 1 only
Measure: Assessment of PK parameter: Area Under the Curve (AUC) computed from time zero to the time of the last positive concentration (AUClast) for REGN10933 Time: Through Day 169Description: Phase 1 only
Measure: Assessment of PK parameter: AUC computed from time zero to the time of the last positive concentration (AUClast) for REGN10987 Time: Through Day 169Description: Phase 1 only
Measure: Assessment of PK parameter: AUC from time zero extrapolated to infinity (AUCinf) for REGN10933 Time: Through Day 169Description: Phase 1 only
Measure: Assessment of PK parameter: AUC from time zero extrapolated to infinity (AUCinf) for REGN10987 Time: Through Day 169Description: Phase 1 only
Measure: Assessment of PK parameter: AUCinf-to-dose ratio (AUCinf/dose) of REGN10933 Time: Through Day 169Description: Phase 1 only
Measure: Assessment of PK parameter: AUCinf-to-dose ratio (AUCinf/dose) of REGN10987 Time: Through Day 169Description: Phase 1 only
Measure: Assessment of PK parameter: Observed terminal half-life [t1/2] for REGN10933 Time: Through Day 169Description: Phase 1 only
Measure: Assessment of PK parameter: Observed terminal half-life [t1/2] of REGN10987 Time: Through Day 169Description: Phase 1 only
Measure: Assessment of PK parameter: Clearance (CL) for REGN10933 Time: Through Day 169Description: Phase 1 only
Measure: Assessment of PK parameter: Clearance (CL) of REGN10987 Time: Through Day 169Description: Phase 1 only
Measure: Assessment of PK parameter: Volume of distribution at steady state (Vss) of REGN10933 Time: Through Day 169Description: Phase 1 only
Measure: Assessment of PK parameter: Volume of distribution at steady state (Vss) of REGN10987 Time: Through Day 169Description: Phase 1 only
Measure: Assessment of PK parameter: Mean residence time (MRT) of REGN10933 Time: Through Day 169Description: Phase 1 only
Measure: Assessment of PK parameter: Mean residence time (MRT) of REGN10987 Time: Through Day 169Provide Compassionate Use access to REGN-COV2 for adult patients with recently diagnosed mild-to-moderate coronavirus disease (COVID-19) who are at high risk for poor outcomes.
Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports